Therapy Landscape for Kidney Cancer
(ODYSSEY RCC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to better understand the treatment of metastatic renal cell carcinoma (mRCC) in real-world settings in the U.S. and its impact on patients' quality of life. It focuses on individuals who have started their first or second round of treatment for mRCC within the last three months. Those who have undergone previous surgery or radiation, or who are currently not on active therapy, can also participate. The trial excludes individuals being treated for other types of cancer.
As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to the validation of a potentially effective treatment.
Why are researchers enthusiastic about this study?
Researchers are excited about this trial because it aims to build a comprehensive database that could transform how we approach treatment for renal cell carcinoma (RCC). Currently, standard treatments for RCC include targeted therapies like tyrosine kinase inhibitors and immunotherapies, which work by either blocking the signals that tumors use to grow or boosting the immune system to attack cancer cells. However, the landscape is rapidly changing, and this database will help track outcomes and effectiveness of emerging therapies. By capturing real-world data, researchers hope to better understand which treatments work best for different patient profiles, ultimately guiding personalized medicine and improving survival rates.
Who Is on the Research Team?
Daniel George, MD
Principal Investigator
Duke University
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Patients undergo consent and baseline assessments, including research blood collection and processing
Follow-up
Patient reported outcomes, quality of life, and medications data are obtained via follow-up phone interviews
What Are the Treatments Tested in This Trial?
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor
Duke Clinical Research Institute
Collaborator
Bristol-Myers Squibb
Industry Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania
Exelixis
Industry Sponsor
Michael M. Morrissey
Exelixis
Chief Executive Officer since 2010
PhD in Chemistry from Harvard University, BSc in Chemistry from the University of Wisconsin
Vicki L. Goodman
Exelixis
Chief Medical Officer since 2022
MD
Merck Sharp & Dohme LLC
Industry Sponsor
Chirfi Guindo
Merck Sharp & Dohme LLC
Chief Marketing Officer since 2022
Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business
Robert M. Davis
Merck Sharp & Dohme LLC
Chief Executive Officer since 2021
JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University
Pfizer
Industry Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University